2-peptide research blend in one vial: Cagrilintide + Semaglutide. Novo Nordisk's fixed-dose combination of the amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide — a once-weekly obesity injection that pairs two complementary appetite pathways, currently under FDA review.
Also known as: Cagrilintide/semaglutide
A blend has one whole-vial purity, but the number that decides what you're holding is the net content of each component — an HPLC run resolves a separate peak for each. So we verify CagriSema component by component. Each links to its own compound page, where its full independent testing lives.
| Component | Typical mg | Role in the blend | Verified purity | |
|---|---|---|---|---|
| Cagrilintide | 2.4 mg | Long-acting amylin analog — enhances satiety signalling | 99.6% · 239 tests | View testing → |
| Semaglutide | 2.4 mg | GLP-1 receptor agonist — reduces appetite, slows gastric emptying | 99.7% · 410 tests | View testing → |
Composition varies by vendor. The components above are consistent across shops, but the milligrams can differ — always dose by the individual component amounts printed on your vial, never by a generic “blend dose.”
A blend is the single hardest product to trust — the whole-vial purity tells you the material is clean, but not whether every peptide is present in the right amount. Two questions decide that, and both are answerable in a lab.
Mass spec (or a clean HPLC peak per compound) confirms each peptide is in the vial — not one short, not a cheaper substitute standing in for the expensive one.
Tested milligrams vs. labelled milligrams, per component. This is where blends fail quietly — one component underdosed to pad margin while the vial still “contains” everything.
Tests run on a CagriSema vial as sold — broken down per component. This is the data no shop and no competitor publishes.
CagriSema is new to the library. Have a COA for a CagriSema vial? Add it — every submission maps back to the 2 component compounds automatically.
Submit a CagriSema lab testUntil more CagriSema vials are tested, the strongest signal is how each component performs in single-compound testing across the shops we track. Tap any card for its full data.
Last Updated: July 2026
CagriSema is a genuine Novo Nordisk fixed-dose combination — not a gray-market stack — pairing cagrilintide (a long-acting amylin analog) with semaglutide (the GLP-1 receptor agonist marketed as Wegovy/Ozempic) in a single once-weekly subcutaneous injection for weight management. Unlike the other blends in this section, it is a formally developed pharmaceutical — but as of 23 July 2026 it is still under FDA review and not approved in the US or EU.
The combination targets appetite through two complementary systems at once: semaglutide's GLP-1 pathway reduces appetite and slows gastric emptying, while cagrilintide's amylin pathway enhances satiety signaling — and in trials the pair produced greater weight loss than either component alone, evidence of genuine synergy. In REDEFINE 1, CagriSema produced 22.7% average weight loss at 68 weeks (trial-product estimand; ~20.4% on the treatment-policy estimand), versus ~16% for semaglutide alone and ~12% for cagrilintide alone. REIMAGINE 2, reported February 2026, added type 2 diabetes data: a 1.91-percentage-point HbA1c reduction and 14.2% weight loss versus semaglutide.
CagriSema is an investigational combination: Novo Nordisk filed a New Drug Application with the FDA on 18 December 2025 (based on REDEFINE 1 and REDEFINE 2), the agency's decision is expected in Q4 2026 — around October on the standard ten-month review clock, though no PDUFA date has been publicly confirmed — and it remains unapproved in both the US and EU; notably, in the REDEFINE 4 head-to-head trial it delivered 23% weight loss but did not meet noninferiority versus tirzepatide. Higher-dose data from REDEFINE 11 is expected in the first half of 2027. Evidence level: Phase 3 complete; under FDA review; not approved (verified 23 July 2026).
Because CagriSema is not yet an approved, dispensable product, anything sold outside a clinical trial is unapproved material of uncertain identity — and a fixed two-peptide combination is exactly the kind of product where mass-spec identity and HPLC purity for both components matter. Peptigrity buys anonymously, tests at independent ISO-accredited labs, and publishes the unedited COA; the trust score weights lab purity and reviews equally (50/50). See how to read lab results.
Educational information only; not medical advice. CagriSema is investigational and not yet approved; verify current regulatory status. Consult a qualified healthcare provider. Peptigrity does not sell, endorse, or recommend products or vendors.
In a blend you can only set the dose of one component — the rest follow the fixed ratio. Our calculator does that math so you don't underdose the peptide you actually care about.
Enter each component's milligrams and your BAC water — get per-component units for one syringe draw.
Open the blend calculator →How much bacteriostatic water, mixing without shaking, storage, and shelf life once mixed.
Read the reconstitution guide →Not yet — Novo Nordisk filed an NDA on 18 December 2025 and an FDA decision is expected in Q4 2026. As of 23 July 2026 it is not approved in the US or EU, and no PDUFA date has been publicly confirmed.
A fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist), once weekly.
22.7% average weight loss at 68 weeks in REDEFINE 1 (trial-product estimand; about 20.4% on the treatment-policy estimand) — more than either component alone — though it delivered 23% but missed noninferiority versus tirzepatide in the separate REDEFINE 4 head-to-head.
No. Peptigrity is an independent review platform, not a medical authority.